Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash Flows From Operating Activities
Net income (loss)	$ 7,684	$ (35,053)
Adjustments to reconcile net income (loss) to net cash and cash equivalents (used in) provided by operating activities:
Stock-based compensation	9,587	6,993
Deferred taxes	(137)	(11,378)
Depreciation and amortization	29,390	28,731
Non-cash operating lease expense	61	0
Non-cash interest	1,973	1,969
Contingent consideration fair value adjustment	1,996	(342)
Asset impairment charges	0	575
Gain on sale of ANDAs	0	(750)
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable, net	(7,486)	(21,884)
Inventories	1,032	(10,852)
Prepaid expenses and other current assets	1,449	1,563
Accounts payable	(800)	4,047
Accrued royalties	(577)	70
Current income taxes payable, net	(261)	1,654
Accrued government rebates	(1,099)	3,948
Returned goods reserve	(3,601)	(903)
Accrued expenses, accrued compensation, and other	2,839	1,186
Net Cash and Cash Equivalents Provided by (Used in) Operating Activities	42,050	(30,426)
Cash Flows From Investing Activities
Acquisition of Novitium Pharma LLC, net of cash acquired	0	(33)
Acquisition of product rights, IPR&D, and other related assets	(4,329)	(229)
Acquisition of property and equipment, net	(4,850)	(3,270)
Proceeds from the sale of long-lived assets	0	750
Net Cash and Cash Equivalents Used in Investing Activities	(9,179)	(2,782)
Cash Flows From Financing Activities
Payments on borrowings under credit agreements	(1,500)	(1,500)
Series A convertible preferred stock dividends paid	(813)	(812)
Proceeds from stock option exercises and ESPP purchases	1,446	206
Proceeds from public offering	80,555	0
Treasury stock purchases for restricted stock vests	(4,086)	(1,601)
Net Cash and Cash Equivalents Provided by (Used in) Financing Activities	75,602	(3,707)
Net Change in Cash, Cash Equivalents, and Restricted Cash	108,473	(36,915)
Cash, cash equivalents, and restricted cash, beginning of period	53,234	105,301
Cash, cash equivalents, and restricted cash, end of period	161,707	68,386
Reconciliation of cash, cash equivalents, and restricted cash, beginning of period
Cash and cash equivalents	161,707	63,385
Restricted cash	0	5,001
Cash, cash equivalents, and restricted cash, end of period	161,707	68,386
Supplemental disclosure for cash flow information:
Cash paid for interest, net of amounts capitalized	15,456	11,400
Cash paid for income taxes	141	124
Right-of-use assets obtained in exchange for lease obligations	4,499	0
Supplemental non-cash investing and financing activities:
Property and equipment purchased and included in accounts payable	$ 539	$ 779